Dyne Therapeutics, Inc. PE Ratio
The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
- Dyne Therapeutics, Inc. pe ratio for the quarter ending 2026-06-30 was -7.09, a change of -4.45 year-over-year.
- Dyne Therapeutics, Inc. pe ratio for the quarter ending 2026-03-31 was -6.63, a change of -3.39 year-over-year.
- Dyne Therapeutics, Inc. pe ratio for the quarter ending 2025-12-31 was -7.23, a change of 0.37 year-over-year.
- Dyne Therapeutics, Inc. pe ratio for the quarter ending 2025-09-30 was -4.26, a change of 8.15 year-over-year.
- Dyne Therapeutics, Inc. pe ratio for fiscal 2026 was -7.09.
- Dyne Therapeutics, Inc. pe ratio for fiscal 2025 was -7.23, a change of 0.37 from fiscal 2024.
- Dyne Therapeutics, Inc. pe ratio for fiscal 2024 was -7.59, a change of -4.13 from fiscal 2023.
- Dyne Therapeutics, Inc. pe ratio for fiscal 2023 was -3.47, a change of 0.37 from fiscal 2022.
- Available history
- 2020-09-30 to 2026-06-30
- Data captured
Historical PE Ratio
Annual PE Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |